Flucelvax Injection, Suspension
NDC Package 83703-084-03

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is approaching its end of marketing date. An upcoming end of marketing date means the product has been delisted but will remain in the NDC database until the end of marketing date is reached. In most cases, the FDA advises firms to use the expiration date of the last lot produced as the end marketing date, reflecting the possibility that the product may still be available even after manufacturing has stopped.

Flucelvax (influenza a virus a/georgia/12/2022 cvr-167 (h1n1) antigen (mdck cell derived, propiolactone inactivated), influenza a virus a/victoria/800/2024 cvr-289 (h3n2) antigen (mdck cell derived, propiolactone inactivated), influenza b virus b/singapore/wuh4618/2021 antigen (mdck cell derived, propiolactone inactivated)) injection is a vaccine administered via intramuscular route. This formulation utilizes a injection, suspension delivery system. Marketed by Bamboo Us Bidco Llc, this product is identified by NDC 83703-084 and is authorized under FDA application BLA125408.

Identification & Billing

NDC Package Code
83703-084-03
Package Description
10 SYRINGE, GLASS in 1 CARTON / .5 mL in 1 SYRINGE, GLASS (83703-084-04)
Product Code
83703-084
11-Digit Billing Format
83703008403

Clinical Specifications

Proprietary Name
Flucelvax
Non-Proprietary Name
Influenza A Virus A/georgia/12/2022 Cvr-167 (h1n1) Antigen (mdck Cell Derived, Propiolactone Inactivated), Influenza A Virus A/victoria/800/2024 Cvr-289 (h3n2) Antigen (mdck Cell Derived, Propiolactone Inactivated), Influenza B Virus B/singapore/wuh4618/2021 Antigen (mdck Cell Derived, Propiolactone Inactivated)
Substance Name
Influenza A Virus A/georgia/12/2022 Cvr-167 (h1n1) Antigen (mdck Cell Derived, Propiolactone Inactivated); Influenza A Virus A/victoria/800/2024 Cvr-289 (h3n2) Antigen (mdck Cell Derived, Propiolactone Inactivated); Influenza B Virus B/singapore/wuh4618/2021 Antigen (mdck Cell Derived, Propiolactone Inactivated)
Dosage Form
Injection, Suspension - A liquid preparation, suitable for injection, which consists of solid particles dispersed throughout a liquid phase in which the particles are not soluble. It can also consist of an oil phase dispersed throughout an aqueous phase, or vice-versa.
Administration Route
Intramuscular - Administration within a muscle.
Active Ingredient(s)

Regulatory & Marketing

Labeler Name
Bamboo Us Bidco Llc
Product Type
Vaccine
FDA Application #
BLA125408
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
07-01-2025
End Marketing Date
07-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 83703-084-03 identifies a specific commercial package of 10 syringe, glass in 1 carton / .5 ml in 1 syringe, glass (83703-084-04) of Flucelvax, a vaccine label labeled by Bamboo Us Bidco Llc. This injection, suspension is formulated for intramuscular use and contains influenza a virus a/georgia/12/2022 cvr-167 (h1n1) antigen (mdck cell derived, propiolactone inactivated); influenza a virus a/victoria/800/2024 cvr-289 (h3n2) antigen (mdck cell derived, propiolactone inactivated); influenza b virus b/singapore/wuh4618/2021 antigen (mdck cell derived, propiolactone inactivated) as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Bamboo Us Bidco Llc on July 01, 2025.

How is this Bamboo Us Bidco Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 83703008403. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
83703-084-03
11-Digit CMS (5-4-2)
83703-0084-03

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.